Valneva files 2024 registration documents in France, US

Valneva SE, a vaccine company based in France, announced the filing of important documents today. On March 24, 2025, the company submitted its 2024 Universal Registration Document to the French Financial Markets Authority (AMF) and its Form 20-F to the U.S. Securities and Exchange Commission (SEC). The Universal Registration Document includes several key reports. It features the 2024 Annual Financial Report, the Annual Management Report, the Corporate Governance Report from the Board of Directors, and a Sustainability Statement. The Sustainability Statement is available in both English and French. These documents can be accessed on Valneva's website, as well as on the AMF and SEC websites. People can request hard copies for free from the company’s location in Saint-Herblain, France. Valneva focuses on creating vaccines for infectious diseases that meet urgent medical needs. The company has a successful history of moving vaccines from research to approval. Valneva currently markets three vaccines for travel, including the first chikungunya vaccine in the world. Revenues from Valneva's vaccines support new research and development. The company is working on a Lyme disease vaccine with Pfizer, a Shigella vaccine, and vaccines for the Zika virus among other health threats. More details about their work can be found on their website.